Results 121 to 130 of about 53,519 (232)

Assessment of Selected Immunophenotypic Markers in Childhood Non‐Hodgkin's Lymphomas in Ghana: A Possible Tool for Effective Stratification of Patients and Assessment of Survival Outcomes

Cancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Non‐Hodgkin lymphomas (NHL) represent a heterogeneous group of malignancies with varying molecular and immunophenotypic characteristics. In Ghana, NHL is the third most common childhood cancer, highlighting the need for precise diagnostic approaches to improve survival rates.
Samuel Asamoah Sakyi, Bernard Gyan, Ernest Adankwah, Ernest Kwasi Adjei, Vivian Paintsil, David Kwabena Adu, Manu Akwasi Owusu, Clement Binwatin Dagungong, Muniru Mohammed Tanko, Kervin Edinam Zogli, Alfred Effah, Samuel Kwame Sopuruchi Agomuo, Samuel Kwarteng, Beatrice Nyantakyiwaa, Edward Osei Gyimah, Harriet Yeboaa Diawuo, George Oduro Owusu, Ebenezer Senu, Oscar Simon Olympio Mensah, Stephen Opoku, Benjamin Amoani, Linda Ahenkorah Fondjo   +21 more
wiley   +1 more source

PIP4K2A depletion suppresses AKT signaling and enhances chemotherapy sensitivity in T-cell lymphoblastic lymphoma cells. [PDF]

Biochem Biophys Res Commun
Chen S, He Z, Ha Y.
europepmc   +1 more source

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma. [PDF]

Cancers (Basel), 2023
Provez L, Putteman T, Landfors M, Roels J, Reunes L, T'Sas S, Van Loocke W, Lintermans B, De Coninck S, Thenoz M, Sleeckx W, Maćkowska-Maślak N, Taghon T, Mansour MR, Farah N, Norga K, Vandenberghe P, Kotecha RS, Goossens S, Degerman S, De Smedt R, Van Vlierberghe P.   +21 more
europepmc   +1 more source

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1027-1040, October 2026.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +1 more source

T-cell lymphoblastic lymphoma of the breast: A retrospective observational study and literature review. [PDF]

Medicine (Baltimore)
Bian W, Yuan J, Fei Y, Feng J, Zhang X, Jin S, Yang Y.   +6 more
europepmc   +1 more source

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree, Amy A. Kirkwood, Nadine Farah, Emma Lawrie, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Bela Patel, Pip Patrick, Paul Smith, Krisztina Z. Alapi, Lingyi Wang, Marc R. Mansour, Adele K. Fielding   +14 more
wiley   +1 more source

Rare <i>NUP98::SETBP1</i> fusion transcript in a refractory adult T-cell lymphoblastic lymphoma. [PDF]

Am J Cancer Res
Chen X, Wang L, Zou J, Zhou J, Zhou Y, Zuo M, Hu L, Dong X, Ke P, Hou J.   +9 more
europepmc   +1 more source

Severe hypophosphataemia in T-cell lymphoblastic lymphoma. [PDF]

BMJ, 1983
P, Colman, B G, Firkin, M B, van der Weyden   +2 more
openaire   +2 more sources

The 9th Edition of the UICC TNM Classification of Malignant Tumours: Updates and Rationale for Change

International Journal of Cancer, Volume 159, Issue 7, Page 1588-1601, 1 October 2026.
ABSTRACT The standard for assessing and recording the extent of the tumour, a necessity for most malignancies, is the Tumour Node Metastases (TNM) classification. The Union for International Cancer Control (UICC) TNM committee has defined this since the early 1950s.
James D. Brierley, Liesbet J. Van Eycken, Meredith E. Giuliani, Brian A. Rous, Shao Hui Huang, Hisao Asamura, Mary K. Gospodarowicz, Anne W. Lee, Brian O'Sullivan   +8 more
wiley   +1 more source

Decoding NOTCH1: From T-Cell Development Guardian to Driver of Pediatric T-Cell Lymphoblastic Lymphoma. [PDF]

Int J Mol Sci
Leijnen F, Lammens T.
europepmc   +1 more source